ReP USP - Resultado da busca

Artigo de periodico
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery (2019)
Goodman, Shaun G; Aylward, Philip E; Szarek, Michael; Chumburidze, Vakhtang; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Hanotin, Corinne; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, REVASCULARIZAÇÃO MIOCÁRDICA, COMPLICAÇÕES PÓS-OPERATÓRIAS, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOODMAN, Shaun G et al. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the american college of cardiology, v. 74, n. 9, p. 1177-1186, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.07.015. Acesso em: 06 jun. 2024.
APA
Goodman, S. G., Aylward, P. E., Szarek, M., Chumburidze, V., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the american college of cardiology, 74( 9), 1177-1186. doi:10.1016/j.jacc.2019.07.015
NLM
Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Nicolau JC. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1177-1186.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1016/j.jacc.2019.07.015
Vancouver
Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Nicolau JC. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1177-1186.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1016/j.jacc.2019.07.015
Artigo de periodico
Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial (2019)
Jukema, J. Wouter; Szarek, Michael; Zijlstra, Laurien E; Silva, H. Asita de; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Goodman, Shaun G; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, ARTERIOSCLEROSE, ANTICORPOS MONOCLONAIS, DISLIPIDEMIAS, ESTATINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JUKEMA, J. Wouter et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, v. 74, n. 9, p. 1167-1176, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.03.013. Acesso em: 06 jun. 2024.
APA
Jukema, J. W., Szarek, M., Zijlstra, L. E., Silva, H. A. de, Bhatt, D. L., Bittner, V. A., et al. (2019). Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, 74( 9), 1167-1176. doi:10.1016/j.jacc.2019.03.013
NLM
Jukema JW, Szarek M, Zijlstra LE, Silva HA de, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1167-1176.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.013
Vancouver
Jukema JW, Szarek M, Zijlstra LE, Silva HA de, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1167-1176.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.013
Artigo de periodico
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial (2019)
White, Harvey D; Steg, Ph. Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Erglis, Andrejs; Goodman, Shaun G.; Nicolau, José Carlos
Source: European heart journal. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, INSUFICIÊNCIA CARDÍACA, ENZIMAS PROTEOLÍTICAS, ESTATINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WHITE, Harvey D et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, v. 40, n. 33, p. 2801-2809, 2019Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehz299. Acesso em: 06 jun. 2024.
APA
White, H. D., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., et al. (2019). Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, 40( 33), 2801-2809. doi:10.1093/eurheartj/ehz299
NLM
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1093/eurheartj/ehz299
Vancouver
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1093/eurheartj/ehz299
Artigo de periodico
Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial (2019)
Steg, Philippe Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Bregeault, Marie-France; Dalby, Anthony J; Diaz, Rafael; Edelberg, Jay M; Goodman, Shaun G; Nicolau, José Carlos
Source: Circulation. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, Philippe Gabriel et al. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, v. 140, n. 2, p. 103-112, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.118.038840. Acesso em: 06 jun. 2024.
APA
Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Bregeault, M. -F., Dalby, A. J., et al. (2019). Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, 140( 2), 103-112. doi:10.1161/CIRCULATIONAHA.118.038840
NLM
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Vancouver
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Artigo de periodico
Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial (2019)
Szarek, Michael; White, Harvey D; Schwartz, Gregory G; Alings, Marco; Bhatt, Deepak L; Bittner, Vera A; Chiang, Chern-En; Diaz, Rafael; Edelberg, Jay M; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES, SÍNDROME CORONARIANA AGUDA, ESTATINAS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SZAREK, Michael et al. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, v. 73, n. 4, p. 387-396, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.10.039. Acesso em: 06 jun. 2024.
APA
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, 73( 4), 387-396. doi:10.1016/j.jacc.2018.10.039
NLM
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039
Vancouver
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2024 jun. 06 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039

USP Schools

ReP

Filtros

Authors

Subjects